Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Perle (PRL) 24-Hour Price Fluctuation of 95.5%: Upbit Listing Announcement Drives Speculative Surge in Korean Market

Perle (PRL) 24-Hour Price Fluctuation of 95.5%: Upbit Listing Announcement Drives Speculative Surge in Korean Market

Bitget PulseBitget Pulse2026/04/27 18:33
Show original
By:Bitget Pulse

Volatility Overview

In the past 24 hours, PRL price surged from a low of $0.21482 to a high of $0.41991, with the current quote at $0.30742, reflecting a price swing of 95.5%. The 24-hour trading volume soared to $193 million–$237 million, a 1934% increase compared to the previous day. The Upbit PRL/KRW trading pair reached a single-day volume of $53.69 million, showing significant net capital inflow and improved liquidity.

Analysis of Unusual Movements

- Listing Announcement on Korea's Upbit Exchange: On April 27 at 17:30 (Korean time), Upbit officially launched PRL/KRW, PRL/BTC, and PRL/USDT trading pairs. After a brief delay to complete an investigation of supply issues, this directly triggered speculative buying in the Korean market, rapidly pushing up the price.

- Bithumb Follows Suit: Bithumb simultaneously launched the PRL/KRW trading pair, further amplifying the trading volume explosion.

- Trading Volume Explosion: The 24-hour volume on the entire network skyrocketed, supporting the price movement from the $0.2111 low to the $0.4199 high. On-chain data did not show abnormal whale transfers, but there was clearly significant capital inflow.

Market Views and Outlook

The mainstream market sentiment is positive. According to CoinGecko, PRL saw a 57.6% increase in the first 24 hours after listing, which the community views as a liquidity injection benefit. However, analysts warn of the common post-listing pullback risk, as seen in similar cases like Onyxcoin and PRL, where trading volume remains high but profit-taking is frequent. In the short term, attention should be paid to the support level test near $0.21.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for informational reference only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales